Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

A 26-year-old male with high testosterone is experiencing diffuse hair thinning despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy. Suggestions include adjusting dutasteride dosage, monitoring iron levels, and consulting a dermatologist for further evaluation.

The conversation discusses using tretinoin with topical minoxidil for hair regrowth, despite previous non-response to minoxidil and concerns about oral minoxidil's heart risks. The user is also on dutasteride and is considering a hair transplant if other options fail.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

The conversation is about finding a reputable place to buy Clascoterone in the US. An alternative treatment, pyrilutamide, is suggested as a strong and official option.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

Quercetin and houttuynia cordata extract may stimulate hair growth by enhancing cellular energy metabolism and increasing growth factor secretion. Quercetin has low oral bioavailability, and its natural tint might stain the scalp if used topically.

The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.

Dr. Couto recommends taking finasteride in the morning to align with peak testosterone and DHT production for better effectiveness. Oral minoxidil is acknowledged as better than topical, but the focus is on stabilizing hair loss with finasteride first.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

Dr. Tsuji is giving online lectures about hair multiplication trials. Users express hope for a cure, but some are skeptical about its timeline.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

The user received trichotest results indicating finasteride is ineffective for them, and they plan to use dutasteride mesotherapy and add cetirizine to minoxidil. They seek advice on incorporating dutasteride into their regimen.

A 25-year-old male experiencing diffuse thinning is advised to address high TSH levels and low iron, and consider treatments like finasteride. Weight loss and improved diet are also suggested to potentially help with hair health.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

Microneedling, ketoconazole, and tretinoin are discussed as hair loss treatments, with tretinoin favored for its long-term benefits and potential to turn minoxidil non-responders into responders. Microneedling is recommended for initial use, ketoconazole for dandruff, and tretinoin for continuous use due to its skin benefits.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

Thicair is a product combining microneedling and subdural vitamins for hair loss, containing ingredients like Panax Ginseng Root Extract and Copper Tripeptide-1. Users are skeptical, with one calling it "quackery."

Topical high-dose vitamin C is discussed as a potential treatment for hair loss due to its ability to inhibit DHT and reduce histamine. Some users express skepticism about its effectiveness compared to treatments like finasteride.